Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM2DMPO)

• Drug Name: Kanamycin Drug Info
• Synonyms: Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside
• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 6032
  ChEBI ID: CHEMBL1384
  CAS Number: CAS 59-01-8
  TTD Drug ID: D0YV1Q
  VARIDT Drug ID: DR01214

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.06	0.00e+0	34/36 (94.44%)	PCNA;MCM6;POLE2;...
Cell cycle	1.94	3.19e-3	110/124 (88.71%)	PCNA;SMC1A;CDC25B;...
Prostate cancer	-1.73	4.32e-2	93/97 (95.88%)	TP53;PIK3CA;PDPK1;...
Primary bile acid biosynthesis	-1.82	1.10e-2	15/17 (88.24%)	CYP7A1;CYP46A1;BAAT;...
Retinol metabolism	-1.91	5.26e-3	41/68 (60.29%)	AOX1;UGT2B15;ADH1A;...
B cell receptor signaling pathway	-1.93	0.00e+0	71/81 (87.65%)	PIK3CA;SYK;FCGR2B;...
Staphylococcus aureus infection	-1.94	0.00e+0	72/95 (75.79%)	PTAFR;ITGAL;FCGR2C;...
Fc gamma R-mediated phagocytosis	-1.97	0.00e+0	79/97 (81.44%)	PIK3CA;SYK;PTPRC;...
Complement and coagulation cascades	-2.07	0.00e+0	76/85 (89.41%)	KLKB1;F13B;PLG;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	24H	Hide ▲